Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions
Once-monthly oral PrEP moves into late-stage trials
HIV acquisition in women with good adherence to TAF/FTC PrEP is rare
Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise
Event-driven PrEP for women may work, modelling study predicts
TAF may be effective as once-weekly PrEP
Danish study finds that STI rates in gay men increase before they start PrEP, not after
More evidence that PrEP works as well for women
Top 5 HIV PrEP stories from CROI 2024
